Katie Kalvaitis
Editorial Director at Healio Cardiac/Vascular Intervention
Editorial Director at Endocrine Today
Editorial Director at Healio
Medical editor & reporter. All tweets my own. @cardiologytoday @gohealio @endocrinetoday @healiowomen
Articles
-
2 weeks ago |
healio.com | Scott Buzby |Erik Swain |Katie Kalvaitis
First transcatheter valve approved for use in asymptomatic patients. Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available treatments to new patient populations. This FDA Recap highlights FDA approval of the first transcatheter aortic valve replacement system for treatment of asymptomatic aortic stenosis and the first leadless left ventricular endocardial pacing device.
-
2 months ago |
healio.com | Katie Kalvaitis
• Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% reduction in LDL cholesterol at 12 weeks in patients with hypercholesterolemia. Results of the phase 2b PURSUIT study, which evaluated AZD0780 (AstraZeneca), an oral small molecule PCSK9 inhibitor, were presented at the American College of Cardiology Scientific Session.
-
2 months ago |
healio.com | Katie Kalvaitis |Richard Smith |Jonathan Kim
• 29 million people completed marathons or half-marathons in the U.S. from 2010 to 2023. • Coronary artery disease was the most common etiology of sudden cardiac arrest among race runners. CHICAGO — Good news for long-distance runners: The incidence of sudden cardiac arrest during marathons and half-marathons remained relatively stable over the past 2 decades, while the risk for sudden cardiac death markedly declined.
-
2 months ago |
healio.com | Erik Swain |Katie Kalvaitis |Mary Walsh
Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function• The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney function. • The effect of tirzepatide on kidney function depends on how CKD is defined, researchers said.
-
2 months ago |
healio.com | Regina Schaffer |Katie Kalvaitis |Keith C. Ferdinand |Luke J. Laffin
Novel agent targeting aldosterone lowers blood pressure for adults with resistant hypertension• A dose-escalation strategy did not result in greater BP lowering. CHICAGO — The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, uncontrolled and “true” treatment-resistant hypertension, according to data from a new phase 2b study.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 252
- Tweets
- 643
- DMs Open
- No
🔥Highlights from day 2 #ACC25 All @GoHealio @CardiologyToday coverage here: https://t.co/5HC8F2VhYj 📌 ALPACA: https://t.co/ZKlRymszwc 📌 BHF PROTECT-TAVI: https://t.co/6pkwuVdqrd 📌 FRESH-UP: https://t.co/kkPhuVXflt 📌 Evolut Low Risk at 5 years, DapaTAVI & more below
Positive data for lepodisiran presented at #ACC25: 📌 resulted in substantial reductions in lipoprotein(a) at 6 months and 1 year vs placebo in phase 2 study 📌 drug will allow infrequent administration 📌 a cardiovascular outcomes trial is underway More in the link below
#Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more than 90 percentage points with a single 400-mg dose compared with placebo @CleClinicHVTI @ACCinTouch #ACC25 #cardiotwitter https://t.co/JfvTFheKsj
New 5-year data from Evolut Low Risk Trial: 📌 At 5 years, no difference in death or disabling stroke between TAVR and surgery in patients at low surgical risk 📌 Both groups had improved QoL 📌 “These results are very encouraging for the TAVR population” More in link below
Among patients with severe aortic stenosis at low surgical risk, TAVR and surgery conferred similar rates of death and disabling stroke at 5 years, new data from the Evolut Low Risk Trial show @HMethodistCV @WeillCornell @ACCinTouch #ACC25 https://t.co/FomgFGMVvR